



Makers Laboratories Limited

Regd. Office : Plot 54D, Kandivli Industrial Estate, Kandivli (W), Mumbai - 400 067

Tel: 022-6111 2800, Fax: 022-6111 2835, E-mail : investors@makerslabs.com, Website : www.makerslabs.com

CIN : L24230MH1984PLC033389

Unaudited Financial Results for the Quarter and Nine Months Ended 31.12.2015

	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2015 (Unaudited)	30.09.2015 (Unaudited)	31.12.2014 (Unaudited)	31.12.2015 (Unaudited)	31.12.2014 (Unaudited)	31.03.2015 (Audited)
PART I							
(Rs. Lacs)							
1.	Income from Operations						
	(a) Net Sales / Income from Operations (Net of excise duty)	1,298.71	1,646.78	1,504.84	4,684.47	5,088.94	6,470.27
	(b) Other Operating Income	0.81	9.56	8.34	12.04	11.99	21.14
	Total Income from Operations (net)	1,299.52	1,656.34	1,513.18	4,696.51	5,100.93	6,491.41
2.	Expenses						
	(a) Cost of Materials consumed	353.07	383.08	417.96	1,268.60	1,519.21	1,946.35
	b) Purchase of stock-in-trade	170.74	540.53	419.50	1,405.29	1,570.42	2,079.96
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	254.98	126.21	146.42	143.04	105.37	9.07
	(d) Employee benefits expense	166.92	157.10	167.85	516.64	509.86	685.99
	(e) Depreciation and amortisation expense	31.64	31.48	39.81	93.74	116.21	152.71
	(f) Other expenses	254.79	317.81	308.01	906.50	1,053.06	1,357.25
	Total Expenses	1,232.14	1,556.21	1,499.55	4,333.81	4,874.13	6,231.33
3.	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	67.38	100.13	13.63	362.70	226.80	260.08
4.	Other Income	17.85	10.20	10.76	42.61	33.61	46.55
5.	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	85.23	110.33	24.39	405.31	260.41	306.63
6.	Finance costs	8.08	9.57	9.48	25.23	31.53	38.24
7.	Profit / (Loss) from ordinary activities after finance cost but before exceptional items (5-6)	77.15	100.76	14.91	380.08	228.88	268.39
8.	Exceptional Items :						
	Reversal of provision for diminution in value of	-	-	(71.60)	-	(71.60)	(71.60)
9.	Profit / (Loss) from ordinary activities before tax (7-8)	77.15	100.76	86.51	380.08	300.48	339.99
10.	Tax expense	28.78	36.75	20.03	136.17	95.13	104.80
11.	Net Profit / (Loss) from ordinary activities after tax (9- 10)	48.37	64.01	66.48	243.91	205.35	235.19
12.	Extraordinary items (net of tax expense)	-	-	-	-	-	-
13.	Net Profit / (Loss) for the period (11-12)	48.37	64.01	66.48	243.91	205.35	235.19
14.	Paid-up equity share capital (Face value of Rs.10/- each)	491.70	491.70	491.70	491.70	491.70	491.70
15.	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	1,970.84
16. i	Earnings Per Share (before extraordinary items) (of Rs. 10/ each)						
	Basic & Diluted (Rs.)	0.98	1.30	1.35	4.96	4.18	4.78
ii	Earnings Per Share (after extraordinary items) (of Rs. 10/ each)						
	Basic & Diluted (Rs.)	0.98	1.30	1.35	4.96	4.18	4.78

Note: 1. The above unaudited financial results as reviewed by the Audit Committee were approved and taken on record by the Board of Directors in their meeting held on February 2, 2016.

2. The Auditors of the Company have carried out the limited review of the above unaudited financial results in terms of Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015.

3. The entire operations of the Company relate to only one segment viz. 'Pharmaceuticals'.

4. Previous year figures have been regrouped, wherever necessary.

Place : Mumbai
Date : February 2, 2016



By Order of the Board

Jatup
Purnima Jain
Whole Time Director
DIN 00937041